Alankit AGM 2026: ₹86 Cr Warrants to Fund ATL

What shareholders approved at the 37th AGM

Alankit Limited shareholders approved the issuance of up to 10,00,00,000 (10 crore) fully convertible warrants at the company’s 37th Annual General Meeting held on September 8, 2026. The warrant issuance was approved through a special resolution and was highlighted as the most significant item under special business. The AGM also placed 26 resolutions before members, as per the voting results referenced in the meeting highlights. The meeting concluded at 11:44 a.m. Alongside the fund-raise, shareholders adopted the FY26 audited accounts. The AGM also re-appointed Ms. Meera Lal, as stated in the AGM outcomes. Multiple related party transactions across group entities were also approved.

Issue structure: preferential allotment of convertible warrants

The approval covers a preferential issue of up to 10 crore fully convertible warrants. Each warrant carries the right to subscribe to one equity share of face value ₹1 each. The issue price was set at ₹8.60 per warrant, aggregating to ₹86 crore for the full size of the proposal. The company noted that the price was higher than the minimum prescribed price. Warrants are convertible at the option of the holder in one or more tranches. The maximum conversion window is 18 months from the date of allotment. The warrants are to be issued to entities in promoter and public categories, as described in the proposed allottee list.

Proposed allottees and allocation details

The AGM material listed two proposed allottees for the warrants. Up to 5,00,00,000 warrants were proposed to be allotted to Alka Agarwal under the promoter and promoter group category. Up to 5,00,00,000 warrants were proposed to be allotted to Ramesh Sawalram Saraogi under the public category. Together, these two allocations add up to the full 10,00,00,000 warrants. The structure indicates a concentrated allotment with two counterparties. The company also indicated that the issue would be on a preferential basis. Shareholder approval was sought and obtained for this specific structure.

Payment terms: 25% upfront, 75% on exercise

The warrants include a staged payment mechanism. Allottees are required to pay at least 25% of the warrant issue price at the time of allotment. The balance 75% is payable upon exercise, when the holder converts the warrants into equity shares. This staged approach aligns with the disclosure that the issue price is ₹8.60 per warrant. Separately, the article text also referenced a split of ₹2.15 per warrant and an exercise price of ₹6.45, which together total ₹8.60. Read alongside the 25% and 75% payment rule, this split corresponds to the upfront and conversion payments for a warrant priced at ₹8.60. The total fund-raise value remains ₹86 crore if all warrants are allotted and fully exercised.

Board approval and the regulatory framework cited

Alankit’s board approved the warrant proposal at its meeting held on August 7, 2026, subject to shareholder approval. The company cited Sections 42 and 62(1)(c) of the Companies Act, 2013 for the issuance process. It also cited Regulation 160 of the SEBI (ICDR) Regulations, 2018. The AGM special resolution was positioned as the member approval required to proceed. The warrants are to be issued on a preferential basis, which typically requires disclosures on pricing and allottee details, both of which were provided in the AGM highlights. The proposal also includes timelines and end-use, which were specified up to a defined date.

Use of proceeds: ₹70 crore for ATL, ₹16 crore corporate purposes

From the ₹86 crore proposed proceeds, the company earmarked ₹70 crore for investment in its wholly owned subsidiary, Alankit Technologies Limited (ATL). The remaining ₹16 crore was earmarked for general corporate purposes. The utilisation timeline provided for both objects extends up to August 31, 2028. The stated purpose for funding ATL is linked to strengthening its capital base. Specifically, the company referenced the applicable net-worth requirement of ₹75 crore prescribed under the SEBI (Custodian) Regulations, 1996. This is in connection with ATL’s proposed application for registration as a Custodian.

Why the ATL funding is tied to custodian registration

The disclosures connect the capital infusion into ATL to regulatory eligibility for a custodian licence. The company said the funds are intended to help meet the net-worth requirement of ₹75 crore under SEBI (Custodian) Regulations, 1996. The funding plan earmarks ₹70 crore for ATL, which is close to the cited regulatory net-worth threshold. The text specifically links the investment to ATL’s proposed application for registration as a Custodian. This provides a defined objective for a large share of the proposed proceeds. The remaining portion of the proceeds is reserved for general corporate purposes, without additional sub-breakup in the provided material. The company also provided an outer timeline for utilisation extending to August 31, 2028.

Key financial snapshot cited in the disclosure

The article text referenced a financial snapshot noting net sales of ₹78 crore and a net profit of ₹5 crore as of June 2026. These figures provide context to the size of the proposed fund raise. With the proposed proceeds of ₹86 crore, the planned capital raise is larger than the cited net sales figure and materially higher than the cited profit figure. The disclosure does not provide additional line items such as debt, cash, or detailed segment information in the provided extract. It also does not specify whether the net sales and profit are quarterly, trailing, or annualised in the same extract. Readers should treat them as the figures explicitly stated “as of June 2026.”

Dilution disclosure on a fully converted basis

The company stated that upon full conversion of warrants, the post-preferential share capital on a fully diluted basis would be ₹37,11,58,100 (about ₹37.12 crore). It also stated that this would be divided into 37,11,58,100 equity shares of face value ₹1 each. This disclosure gives an indication of the fully diluted equity base after conversion of all proposed warrants. The extract does not provide the pre-issue equity share count in the same section. It also does not provide a per-share earnings impact calculation, and none is inferred here. The conversion remains contingent on warrant exercise within 18 months of allotment.

Summary table: terms, parties, and dates

Proceeds allocation and stated timeline

Market relevance: what this approval signals

For investors tracking small and mid-cap fund raises, the AGM approval is a formal step that enables Alankit to proceed with the preferential warrant issuance, subject to applicable approvals and processes. The disclosures clearly tie most of the proposed proceeds to a specific subsidiary-level objective, namely ATL’s custodian registration plan. The split payment structure means cash inflows may be staged, with at least 25% payable at allotment and the remainder on conversion. The conversion window of 18 months sets a time boundary for the potential move from warrant capital to equity. The company also provided a fully diluted share capital figure, which helps frame the potential equity base after conversion. Separately, Alankit is described as the flagship company of the Alankit Group and operates in India’s financial and e-Governance services sector.

Conclusion

Alankit’s 37th AGM on September 8, 2026 approved a preferential issue of up to 10 crore fully convertible warrants priced at ₹8.60 each, aggregating ₹86 crore, with ₹70 crore earmarked for ATL and ₹16 crore for general corporate purposes. The company has linked the ATL investment to meeting the ₹75 crore net-worth requirement under SEBI (Custodian) Regulations, 1996 for a proposed custodian registration application. The board approval date (August 7, 2026), conversion window (18 months), and utilisation deadline (up to August 31, 2028) provide the key milestones disclosed for tracking next steps.